Small cell lung cancer is the most invasive type of lung cancer, with high degree of malignancy, rapid cell proliferation and rapid disease progression. Patients with small cell lung cancer will have distant metastasis in the early stage, and 2 / 3 of patients are in the advanced stage at the first diagnosis. These patients are also known as patients with extensive small cell lung cancer. Their cancer cells often spread to the whole lung or other parts of the body, especially brain metastasis and liver metastasis. The 5-year average survival rate is only 3%.
In clinical treatment, the last thing many doctors want to face is small cell lung cancer. Yu Jinming, academician of the Chinese Academy of engineering and President of Shandong Cancer Hospital, said: "small cell lung cancer is one of the worst biological behavior and prognosis, especially in the late stage. Its treatment scheme has made very slow progress in the past two years. The treatment strategy of chemotherapy scheme has been used for many years, and there is still no new progress." Although the initial response of most patients with small cell lung cancer to chemotherapy drugs is good, the maintenance time of curative effect is short, and the probability of recurrence within 6 months after treatment is very high. Once relapse occurs, the condition tends to deteriorate rapidly, and the effect of follow-up treatment is poor. The average life span of patients after first-line chemotherapy is only about 10 months.
So, is it possible for this cancer to be detected early through screening technology? Cheng Ying, Party Secretary of Jilin cancer hospital and vice president of Chinese society of Clinical Oncology, said: "Small cell lung cancer lacks early symptoms. Now the lung cancer screening is more to screen ground glass nodules, which may not be able to find tumors earlier. Once the symptoms of small cell lung cancer appear, they are late, such as cough, expectoration, blood in sputum, chest pain, fatigue and so on. If we check chest CT once a year, due to the rapid proliferation of small cell lung cancer, we can When you can't find it, it has grown very big. "
With the continuous development of medicine, the emergence of targeted therapy and immunotherapy has created a new field of lung cancer treatment. Targeted therapy refers to the use of different targeted drugs to block the signal transduction of cancer cells and hinder the growth of cancer cells for the identified carcinogenic sites. Its systemic side effects are small, which makes many patients with advanced non-small cell lung cancer obtain long-term survival and higher survival Live quality.
"The latest clinical research results have made a breakthrough. The first-line treatment of PD-L1 inhibitor combined with chemotherapy for advanced small cell lung cancer has made the median overall survival of patients more than one year, which is a revolutionary contribution to us." At present, this treatment method has been unanimously recommended by the national comprehensive cancer network of the United States, the Chinese society of clinical oncology and other authoritative guidelines at home and abroad.
"I believe that in the future, with the further development of innovative therapies such as immunotherapy, as well as the integration of multi-disciplinary, multi-disciplinary and multi fields such as immunotherapy, precision testing, precision therapy and radiotherapy, the treatment of small cell lung cancer will achieve greater breakthroughs, more patients with small cell lung cancer will benefit from advanced innovative therapies, and their overall survival time and quality of life will be further improved , realize the real sense of longevity, "Yu Jinming said.
Source: People's daily
http://health.people.com.cn/n1/2021/1102/c14739-32271008.html
